CLAIMS

20

- 1. Drug-containing sustained release microparticles characterized by comprising a drug other than human growth hormone and a porous apatite derivative.
- Drug-containing sustained release
  microparticles characterized by comprising a drug other than
  human growth hormone, a porous apatite derivative and a
  water-soluble bivalent metal compound.
- 3. The drug-containing sustained release

  10 microparticles according to claim 1 or 2, characterized in that the porous apatite derivative is a porous apatite derivative in which a portion of calcium as a constituent of hydroxyapatite is substituted with zinc during production.
- 4. The drug-containing sustained release

  15 microparticles according to claim 3, characterized in that
  the porous apatite derivative has a zinc substitution rate
  or zinc content rate of 0.1 to 2.0.
  - 5. The drug-containing sustained release microparticles according to claim 2, characterized in that the water-soluble bivalent metal compound is a zinc compound.
  - 6. The drug-containing sustained release microparticles according to claim 5, characterized in that the water-soluble bivalent metal compound is zinc chloride or zinc acetate.
- 7. A preparation for parenteral administration characterized by comprising, drug-containing sustained release microparticles according to any of claims 1 to 6.

- 8. The preparation according to claim 7, characterized in that the preparation for parenteral administration is either a subcutaneous injection or an intramuscular injection.
- 9. A process for producing drug-containing sustained release microparticles characterized by comprising: dispersing under agitation microparticles of a porous apatite derivative in an aqueous solution containing a drug so that the aqueous solution infiltrates into the porous apatite derivative; adding thereto an aqueous solution containing a water-soluble bivalent metal compound so that the water-soluble bivalent metal compound infiltrates into the porous apatite derivative; further adding an additive such as a stabilizer to the mixture; and effecting lyophilization or vacuum-drying.
  - 10. The production process according to claim 9, characterized in that the porous apatite derivative is a porous apatite derivative in which a portion of calcium as a constituent of hydroxyapatite is substituted with zinc during production.
  - 11. The production process according to claim 10, characterized in that the porous apatite derivative has a zinc substitution rate or zinc content rate of 0.1 to 2.0.
- 12. The process according to claim 9, characterized
  25 in that the water-soluble bivalent metal compound is zinc chloride or zinc acetate.

20